Role of Wnt/β-Catenin Pathway in Cancer Signaling

2018 ◽  
pp. 289-295 ◽  
Author(s):  
Casey D. Stefanski ◽  
Jenifer R. Prosperi
Keyword(s):  
2018 ◽  
pp. 263-270 ◽  
Author(s):  
Nicci Owusu-Brackett ◽  
Maryam Shariati ◽  
Funda Meric-Bernstam
Keyword(s):  

2018 ◽  
Vol 114 (3) ◽  
pp. 32a
Author(s):  
Stephen G. Sligar ◽  
Michael C. Gregory ◽  
Mark A. McLean
Keyword(s):  

2019 ◽  
Vol 46 (3) ◽  
pp. 3545-3555 ◽  
Author(s):  
Richa Mehra ◽  
Satej Bhushan ◽  
Felix Bast ◽  
Sandeep Singh

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 3100
Author(s):  
Giampaolo Morciano ◽  
Bianca Vezzani ◽  
Sonia Missiroli ◽  
Caterina Boncompagni ◽  
Paolo Pinton ◽  
...  

Yes-associated protein (YAP) has emerged as a key component in cancer signaling and is considered a potent oncogene. As such, nuclear YAP participates in complex and only partially understood molecular cascades that are responsible for the oncogenic response by regulating multiple processes, including cell transformation, tumor growth, migration, and metastasis, and by acting as an important mediator of immune and cancer cell interactions. YAP is finely regulated at multiple levels, and its localization in cells in terms of cytoplasm–nucleus shuttling (and vice versa) sheds light on interesting novel anticancer treatment opportunities and putative unconventional functions of the protein when retained in the cytosol. This review aims to summarize and present the state of the art knowledge about the role of YAP in cancer signaling, first focusing on how YAP differs from WW domain-containing transcription regulator 1 (WWTR1, also named as TAZ) and which upstream factors regulate it; then, this review focuses on the role of YAP in different cancer stages and in the crosstalk between immune and cancer cells as well as growing translational strategies derived from its inhibitory and synergistic effects with existing chemo-, immuno- and radiotherapies.


Sign in / Sign up

Export Citation Format

Share Document